Provera is an oral tablet product containing medroxyprogesterone acetate. It is used when a clinician identifies a hormonal reason for absent or irregular bleeding and can also provide endometrial…
Provera is an oral tablet product containing medroxyprogesterone acetate. It is used when a clinician identifies a hormonal reason for absent or irregular bleeding and can also provide endometrial protection during certain hormone replacement therapy regimens.
The progestin effect creates a controlled hormonal signal that can trigger a withdrawal bleed after a prescribed course.
Provera contains medroxyprogesterone acetate. How much to use and how often depends on the purpose of treatment and is agreed with a doctor or pharmacist. Medroxyprogesterone acetate is a synthetic progestin: it acts in a similar way to the body’s progesterone, while having a different chemical structure and duration of action.
Provera contains medroxyprogesterone acetate. How much to use and how often depends on the purpose of treatment and is agreed with a doctor or pharmacist. Medroxyprogesterone acetate is a synthetic progestin: it acts in a similar way to the body’s progesterone, while having a different chemical structure and duration of action.
Provera is used where a clinician has identified a hormonal reason for absent or irregular bleeding. Before treatment for abnormal uterine bleeding, pregnancy and non-hormonal causes such as fibroids, polyps, infection, thyroid disease, or cervical and endometrial conditions need appropriate assessment.
The main uses include:
Oestrogen encourages the endometrium to grow. Progesterone and progestins counterbalance that growth. In HRT, adding a progestin can reduce the risk of endometrial hyperplasia, which means excessive thickening of the uterine lining.
A missed period is not automatically a reason to start a progestin course. Pregnancy testing and assessment of the cause matter first.
NICE guidance on menopause management describes the need for progestogen protection alongside systemic oestrogen in women with an intact uterus [2].
This medication is not for you if you are pregnant, have unexplained vaginal bleeding that has not been assessed, have a known allergy to medroxyprogesterone acetate, or have active serious liver disease.
It may also be unsuitable for people with a current or previous blood clot, stroke, certain hormone-sensitive cancers, or a history of severe depression that worsened with hormonal treatment. A prescriber weighs these factors against the reason for treatment.
Tell the prescriber about medicines that can alter hormone handling in the liver. Rifampicin, carbamazepine, phenytoin, phenobarbital, and St John’s wort can reduce progestin exposure. Aminoglutethimide may also lower medroxyprogesterone acetate concentrations.
The clotting risk is most relevant when progestins are used with oestrogen-containing HRT, or when a person has personal risk factors such as smoking, obesity, prolonged immobility, or a previous venous thromboembolism.
Do not start Provera if you are pregnant, have unexplained vaginal bleeding, are allergic to medroxyprogesterone acetate, or have serious liver disease. Speak with a prescriber before use if you have had a blood clot or stroke, have certain hormone-sensitive cancers, or have experienced severe depression with hormonal treatment.
Most people prescribed a short course tolerate Provera without serious problems. Headache, dizziness, nausea, breast tenderness, abdominal discomfort, bloating, mood changes, acne, and altered bleeding patterns can occur. Spotting or a heavier-than-expected withdrawal bleed may be frustrating, yet it can happen while the endometrium responds to changing hormone levels.
Weight change is sometimes reported during progestin therapy, though a short course does not prove that the medicine caused body-fat gain. Fluid retention, appetite changes, and natural cycle variation can all affect the scales.
Seek urgent medical assessment for:
The FDA lists headache, nausea, breast tenderness, irregular bleeding, and dizziness among reported reactions with oral medroxyprogesterone acetate [4].
Progesterone receptors are found in the endometrium, the tissue lining the uterus. When medroxyprogesterone activates these receptors, it changes the endometrium from a growth-focused state into a more stable, secretory state. When the course ends and progestin levels fall, the lining may shed as a withdrawal bleed.
This response is why Provera can be useful when periods have stopped because ovulation has not occurred regularly. It does not force an immediate period in every person.
The HPRA product information for oral medroxyprogesterone acetate describes its role in secondary amenorrhoea, dysfunctional uterine bleeding, and endometrial protection with oestrogen therapy [1].
Taking the tablets at random times can make a short regimen harder to interpret. A phone reminder is more reliable than relying on memory.
Another frequent mistake is assuming that the same course suits every missed period. Secondary amenorrhoea can arise from pregnancy, polycystic ovary syndrome, major weight change, thyroid disorders, high prolactin, perimenopause, or stress-related hypothalamic changes. The treatment plan needs to fit the cause.
Do not use Provera as emergency contraception. Do not use it as a substitute for a pregnancy test when a period is late. Avoid starting a leftover course from a previous prescription without a clinician confirming that the reason for treatment is the same.
Provera tablets and depot medroxyprogesterone acetate injections contain related active medicine, yet they are used in very different ways. Tablets provide a short, controllable course. Depot injections release medicine slowly over an extended period and are used for long-acting contraception or selected specialist indications.
| Formulation | How it is given | Typical clinical role |
|---|---|---|
| Provera tablets | Oral tablets taken for a prescribed course | Amenorrhoea, hormonal bleeding, HRT endometrial protection |
| Depot medroxyprogesterone injection | Intramuscular or subcutaneous injection | Long-acting contraception and specialist treatment plans |
Depot injections can delay the return of fertility after stopping and may affect bone mineral density with prolonged contraceptive use. These considerations do not apply in the same way to a short oral Provera course.
The FDA prescribing information for depot medroxyprogesterone acetate includes a warning about bone mineral density loss with long-term use [3].
The best hormonal option depends on the goal: producing a withdrawal bleed, protecting the endometrium during HRT, controlling heavy bleeding, or avoiding systemic hormone exposure. Oral medroxyprogesterone acetate is one option, not a universal substitute for every menstrual concern.
| Hormonal approach | Main pharmacological feature | Situations where it may be considered |
|---|---|---|
| Medroxyprogesterone acetate | Synthetic oral progestin with a defined course | Amenorrhoea, hormonal bleeding, HRT progestogen phase |
| Micronised progesterone | Progesterone structurally identical to endogenous hormone | HRT regimens where a clinician prefers this option |
| Levonorgestrel-releasing intrauterine system | Local progestin effect within the uterus | Long-term heavy menstrual bleeding control or endometrial protection |
Micronised progesterone may cause drowsiness in some people, so it is often scheduled at night. A levonorgestrel intrauterine system requires insertion and can cause irregular bleeding early on. Provera tablets offer the advantage of a time-limited oral course, while the drawback is that tablets depend on consistent daily use.
In clinical practice, doctors often focus less on producing a bleed and more on the reason bleeding stopped or became irregular. A withdrawal bleed after Provera can show that the endometrium responded to progestin, but it does not by itself identify why ovulation was absent.
For HRT, clinicians usually plan the progestogen component alongside the oestrogen regimen rather than adding it only after unexpected bleeding starts. New bleeding after menopause, persistent spotting, or bleeding that returns after treatment needs assessment rather than repeated self-directed courses.
A useful expectation is simple: Provera changes the hormonal environment, and the visible result may appear after treatment ends.
Alcohol does not have a major direct interaction with medroxyprogesterone acetate listed in standard prescribing information. It can still worsen dizziness, headache, nausea, low mood, or sleep disruption, which are symptoms some people experience during hormonal treatment. The HPRA product information available in 2023 does not identify alcohol as a specific contraindication, but moderation is sensible if Provera makes you feel light-headed. Avoid alcohol if you develop severe dizziness or are taking other medicines that cause sedation. Seek medical advice if these symptoms are severe or persistent.
Keep Provera tablets in a dry place at normal room temperature, away from direct heat, moisture, and children. Bathrooms and a car glove compartment are poor choices because temperatures and humidity can vary widely. During travel, keep the tablets in a secure hand-luggage compartment rather than leaving them in checked baggage or a hot vehicle. FDA prescribing information updated in 2024 advises controlled room-temperature storage for oral medroxyprogesterone acetate products.
Age alone does not prevent use, but the reason for bleeding becomes more significant after menopause. Any vaginal bleeding after menopause requires clinical assessment before hormonal treatment because it can have causes unrelated to hormone fluctuation. For women using HRT, the progestogen choice is linked to the oestrogen regimen, uterus status, clot history, liver health, and breast cancer history. NICE menopause guidance, updated in 2024, supports individualised HRT decisions rather than a one-size-fits-all progestogen plan.
The medicine begins acting on progesterone receptors after it is absorbed, yet the outcome a person notices depends on the treatment goal. For a prescribed withdrawal bleed, the visible effect often occurs after the course has finished, rather than on the first day of tablets. Bleeding may vary in timing and amount, and some people experience spotting first. The FDA oral medroxyprogesterone acetate prescribing information from 2024 describes bleeding-pattern changes as part of the expected hormonal response.
Provera should not be used in known or suspected pregnancy unless a specialist has advised otherwise for a specific reason. A late period should be assessed for pregnancy before beginning treatment for amenorrhoea or menstrual delay. During breastfeeding, medroxyprogesterone can pass into milk in small amounts, and the timing and clinical purpose need individual review. LactMed’s 2025 monograph on medroxyprogesterone acetate discusses milk transfer and breastfeeding considerations.
For the short oral courses commonly used for menstrual regulation, stopping on the scheduled final day is expected and does not usually require dose tapering. The fall in progestin effect can trigger shedding of the endometrium, resulting in withdrawal bleeding. Do not extend the course or stop it early because of spotting without contacting the prescriber who set the regimen. WHO guidance published in 2022 on contraceptive and hormonal care reinforces that regimen changes should be based on the treatment purpose and individual clinical context.
Choose a time that you can maintain consistently each day. Morning works well for some people, while evening suits those who notice nausea or mild dizziness and prefer to take the tablet after food. There is no universal best hour for every patient, since the prescribed schedule and personal tolerance matter more than the clock time. The HPRA’s 2023 information for medroxyprogesterone acetate supports regular daily administration according to the prescribed regimen.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
I took the prescribed 10 mg course after several months without a period. I had mild breast tenderness and felt bloated for a few days. The bleed started four days after I finished, which was what my doctor had prepared me for.
10 Nov 2026My periods had become very irregular during perimenopause. I remembered the tablets each evening and had spotting near the end of the course, so I worried it had failed. The proper bleed arrived after I stopped, but I found the moodiness uncomfortable.
14 Oct 2026I used it as part of my HRT plan. I had a headache on the first two days and switched to taking it after dinner, which suited me better. The predictable monthly bleeding was inconvenient, though I preferred knowing what to expect.
5 Nov 2026I was prescribed Provera after tests for absent periods. I missed one tablet and then took two the next day, which gave me cramps and unexpected spotting. After speaking with the clinic, I followed the next plan exactly and the timing was much clearer.
23 Oct 2026
